Rodman & Renshaw Maintains Unity Biotechnology(UBX.US) With Buy Rating, Cuts Target Price to $8
Unity Biotechnology Analyst Ratings
Unity Biotechnology Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Unity Biotechnology Analyst Ratings
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Foselutoclax Trial Results and Strong Financial Position
Unity Biotechnology Analyst Ratings
Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment
Unity Biotechnology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Unity Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $10 Price Target
Unity Biotechnology Analyst Ratings
Unity Biotechnology's Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy Rating
Analysts Offer Insights on Healthcare Companies: Unity Biotechnology (UBX) and Rockwell Med (RMTI)
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)
Unity Biotechnology (UBX) Receives a Buy From Mizuho Securities
Unity Biotechnology Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on Unity Biotechnology (UBX)
The Latest Analyst Ratings for Unity Biotechnology
Wedbush Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $2